You have 9 free searches left this month | to do more

idarubicin

Idarubicin is a drug used to treat Leukemia, Acute Myeloid Leukemia, and Myelodysplastic Syndromes. Idarubicin is being actively studied in 37 studies and prior, has been studied in 84.

Top SponsorsTop SitesTop Investigators
M.D. Anderson Cancer CenterM D Anderson Cancer CenterAmir Fathi
European Organisation for Research and Treatment of Cancer - EORTCLeiden University Medical CenterProf. Dr. Richard Schlenk
National Cancer Institute (NCI)Roswell Park Cancer InstituteQifa Liu
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients - 2018
Terminated
Has Results
  • Acute Myeloid Leukemia
  • Chicago, Illinois
    University of Illinois at Chicago
2021-07-01
Jul 1, 2021
G
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) - 2018
Completed
Has Results
  • Acute Myeloid Leukemia (Relapsed/Refractory)
  • Frankfurt am Main, Hessen, Germany
  • +2 more
2021-08-01
Aug 1, 2021
H
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) - 2020
Completed
Has Results
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Idarubicin
  • +2 more
  • Tampa, Florida
  • +1 more
2020-12-01
Dec 1, 2020
C
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia - 2018
Terminated
Has Results
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • +8 more
  • Duarte, California
    City of Hope Medical Center
2022-03-28
Mar 28, 2022
M
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruiting
  • Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-10-27
Oct 27, 2021
U
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Tucson, Arizona
  • +2 more
2021-10-14
Oct 14, 2021
C
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
Recruiting
  • AML, Adult
  • Chemotherapy Effect
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
2022-02-28
Feb 28, 2022
M
Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia - 2020
Completed
  • Untreated Adult Acute Myeloid Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
2020-11-28
Nov 28, 2020
T
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Recruiting
  • Acute Promyelocytic Leukemia
  • Arsenic trioxide
  • +6 more
  • Multiple Locations, France
  • +7 more
2022-03-22
Mar 22, 2022
R
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Withdrawn
  • Leukemia
  • recombinant interferon alfa
  • +7 more
  • Chicago, Illinois
  • +3 more
2021-10-06
Oct 6, 2021
P
Clinical Guidelines for APL Treatment
Recruiting
  • APL
  • Valencia, Spain
    Hospital La Fe
2021-03-22
Mar 22, 2021
M
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Recruiting
  • Acute Biphenotypic Leukemia
  • +13 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-15
Feb 15, 2022
M
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Recruiting
  • Acute Myeloid Leukemia
  • Duarte, California
  • +2 more
2022-01-21
Jan 21, 2022
M
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) - 2020
Completed
Has Results
  • Leukemia
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-09-09
Sep 9, 2021
N
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia - 2019
Completed
  • Acute Myeloid Leukemia
  • Idarubicin
  • +4 more
  • Augusta, Georgia
  • +1 more
2020-06-03
Jun 3, 2020
M
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML - 2018
Completed
Has Results
  • Acute Myeloid Leukemia
  • Boston, Massachusetts
  • +1 more
2020-04-23
Apr 23, 2020
D
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) - 2017
Completed
Has Results
  • Acute Myeloid Leukemia
  • Tokyo, Japan
    (unnamed)
2021-07-26
Jul 26, 2021
L
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
Recruiting
  • Acute Myeloid Leukemia
  • Lanzhou, Gansu, China
    Long Zhao
2021-10-07
Oct 7, 2021
S
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Recruiting
  • Acute Myeloid Leukemia
  • Orange, California
  • +3 more
2022-04-05
Apr 5, 2022
U
Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine - 2016
Completed
  • Acute Myeloid Leukemia (AML)
  • Innsbruck, Austria
  • +43 more
2020-12-29
Dec 29, 2020
M
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia - 2019
Completed
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2019-11-14
Nov 14, 2019
C
Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission
Active, not recruiting
  • Leukemia
  • aldesleukin
  • +9 more
  • (no location specified)
2022-02-17
Feb 17, 2022
F
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients
Recruiting
  • AML in Remission
  • Idarubicin
  • ID cytarabine
  • Fuzhou, Fujian, China
    Fujian Medical University Union Hospital
2020-01-01
Jan 1, 2020
A
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia - 2021
Completed
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +9 more
2021-08-24
Aug 24, 2021
S
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Recruiting
  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Lymphoma
  • Palo Alto, California
  • +6 more
2022-03-09
Mar 9, 2022